View Older Stories
-
Novavax (NVAX) Reiterated at Overweight by Cantor Fitzgerald: Nuvaxovid Sales Good
-
FDA may add black box warning to Covid-19 vaccines, CNN says
-
Shares of vaccine makers drop after FDA memo flags reports of child deaths
-
Novavax completes US marketing transfer to Sanofi, receives $25 million
-
Novavax (NVAX) PT Raised to $11 at H.C. Wainwright
-
Cantor Fitzgerald Assumes Novavax (NVAX) at Overweight
-
Novavax signs deals to consolidate facilities, nets $60 million in cash
-
Shah Capital pushes for Novavax (NVAX) sale
-
Novavax completes EU vaccine authorization transfer, receives $25 million
-
Acting CDC head Jim O’neill: I call on vaccine manufacturers to develop safe monovalent vaccines to replace the combined MMR - X post
-
Novavax expands Sanofi license for Matrix-M adjuvant use
-
Rfk Jr. Weighs Expansion Of Vaccine Injury Program: Adviser - Bloomberg
-
Pfizer, Moderna, BioNTech trade lower amid report of vaccine link to child deaths
-
US officials plan to link 25 child deaths to covid shots - WaPo
-
Novavax receives Takeda milestone payment after Japan approves COVID vaccine
-
Rfk Jr. Moves To Add More Hand-picked Vaccine Advisory Members - Bloomberg
-
H.C. Wainwright Assumes Novavax (NVAX) at Buy
-
Novavax receives FDA approval for 2025-2026 COVID-19 vaccine formula
-
FDA Authorizes Covid Vaccines For Those At Higher Risk - Kennedy
-
Novavax refinances convertible debt with $225 million notes due 2031
-
BofA Securities Downgrades Novavax (NVAX) to Underperform
-
Novavax (NVAX) Tops Q2 EPS by 68c ; Offers Guidance
-
Novavax (NVAX) PT Lowered to $8 at TD Cowen
-
Novavax H5N1 vaccine shows immune response in primate study
-
Novavax (NVAX) call put ratio 19 calls to 1 put with a focus on July 25 weekly 8 calls
-
Citi Starts Novavax (NVAX) at Sell
-
Novavax's (NVAX) COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses
-
Kennedy Removing All Members Of CDC Panel Advising On Vaccines
-
Novavax (NVAX) eliminates COO position
-
Biotech stocks Q1 earnings review
-
Increasing unusual option volume: APPN FNKO NVAX SOC UNH CYH EXEL SPCE WTI VTR OMEX
-
JPMorgan on Novavax (NVAX): 'Share Gain Likely Short-Lived Given Gap 2025 Commercial Year'
-
Novavax (NVAX): U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine
-
Novavax (NVAX) Tops Q1 EPS by $3.36
-
Trump: Dr. Casey Means Nominated For Surgeon General
-
Novavax (NVAX) Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid in Japan
-
Novavax (NVAX) Appoints Charles Newton to its Board
-
FDA Asks Novavax (NVAX) to Complete New Study for Delayed Covid-19 Shot's Approval, Sources Say -- WSJ
-
Novavax (NVAX) Says FDA Requested Additional Clinical Data
-
Novavax (NVAX) 16500 contracts of December 2 puts purchased for 48c
-
Novavax (NVAX): SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA
-
Novavax (NVAX) PT Lowered to $10 at BofA Securities
-
Novavax (NVAX) Falls 24% Following Comments from RFK Jr.
-
Novavax (NVAX): We continue to wait on action from FDA, have not yet received an official decision
-
FDA misses Novavax (NVAX) Covid-19 Vaccine deciscion deadline - WSJ
-
Novavax (NVAX) Announces Changes to Board of Directors
-
CDC Plans Large Study Into Potential Connections Between Vaccines and Autism - Reuters
-
Novavax (NVAX) Sees Over $250M In Oper Cost Savings Beginning In 2025 - Slides
-
Novavax (NVAX) Tops Q4 EPS by 9c
-
Clorox (CLX) gains 2.7% on new virus concerns

